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ABSTRACT 31 
Background: Osteoarthritis remains one of the greatest causes of morbidity and mortality in 32 
the equine population. The inability to detect pre-clinical changes in osteoarthritis has been 33 
a significant impediment to the development of effective therapies against this disease. 34 
Synovial fluid represents a potential source of disease-specific small non-coding RNAs 35 
(sncRNAs) that could aid in the understanding of the pathogenesis of osteoarthritis. We 36 
hypothesised that early stages of osteoarthritis would alter the expression of sncRNAs, 37 
facilitating the understanding of the underlying pathogenesis  and potentially provide early 38 
biomarkers.  39 
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Methods:  Small RNA sequencing was performed using synovial fluid from the 40 
metacarpophalangeal joints of both control and early osteoarthritic horses. A group of 41 
differentially expressed sncRNAs was selected for further validation through qRT-PCR using 42 
an independent cohort of synovial fluid samples from control and early osteoarthritic 43 
horses. Bioinformatic analysis was performed in order to identify putative targets of the 44 
differentially expressed microRNAs and to explore potential associations with specific 45 
biological processes. 46 
Results: Results revealed 22 differentially expressed sncRNAs including 13 microRNAs; miR-47 
10a, miR-223, let7a, miR-99a, miR-23b, miR-378, miR-143 (and six novel microRNAs), four 48 
small nuclear RNAs; U2, U5, U11, U12, three small nucleolar RNAs; U13, snoR38, snord96, 49 
and one small cajal body-specific RNA; scarna3. Five sncRNAs were validated; miR-223 was 50 
significantly reduced in early osteoarthritis and miR-23b, let-7a-2, snord96A and snord13 51 
were significantly upregulated. Significant cellular actions deduced by the differentially 52 
expressed microRNAs included apoptosis (P < 0.0003), necrosis (P < 0.0009), autophagy (P < 53 
0.0007) and inflammation (P < 0.00001). A conservatively filtered list of 57 messenger RNA 54 
targets was obtained; the top biological processes associated were regulation of cell 55 
population proliferation (P < 0.000001), cellular response to chemical stimulus (P < 56 
0.000001) and cell surface receptor signalling pathway (P < 0.000001). 57 
Conclusions: Synovial fluid sncRNAs may be used as molecular biomarkers for early disease 58 
in equine osteoarthritic joints. The biological processes they regulate may play an important 59 
role in understanding early osteoarthritis pathogenesis. Characterising these dynamic 60 
molecular changes could provide novel insights on the process and mechanism of early 61 
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osteoarthritis development and is critical for the development of new therapeutic 62 
approaches. 63 
 64 
KEYWORDS: equine, synovial fluid, osteoarthritis, small non-coding RNAs 65 
 66 
BACKGROUND 67 
Osteoarthritis (OA) remains one of the greatest causes of morbidity and mortality for horses 68 
in the UK [1, 2]. Additionally, it is the most common disease affecting the joints in humans, 69 
and a significant cause of pain and disability worldwide [3]. This degenerative, age-related 70 
joint disease is characterised by a progressive degradation of articular cartilage and 71 
concomitant structural and functional change of all joint constituents, including the synovial 72 
membrane, the subchondral bone and periarticular tissues [4]. Of multifactorial origin, OA is 73 
a product of genetic, mechanical and environmental factors such as age, trauma and 74 
occupation [4, 5]. Despite its high prevalence and significant welfare and economic impact, 75 
its pathophysiology remains poorly understood and currently available diagnostic tools can 76 
only identify the disease when cartilage has already exceeded its capacity for intrinsic  repair, 77 
and changes can no longer be reversed [6, 7]. As a result, the development of effective 78 
treatments is also compromised, and currently recommended therapies are mainly 79 
symptomatic. 80 
In the search for molecular biomarkers that could reveal pre-clinical phases of the disease, 81 
scientists have focused much of their attention on microRNAs (miRNAs), the best 82 
characterised family of small non-coding RNAs. Evolutionarily conserved, these 17-22 83 
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nucleotide long molecules regulate gene expression at post-transcriptional level generally 84 
by repressing translation or increasing degradation of messenger RNAs  (mRNAs). They are 85 
involved in different cellular pathways and intercellular communication thus influencing 86 
tissue homeostasis [8]. As such, miRNA profiles can be altered as a result of cellular damage 87 
and/or tissue injury and altered expression of certain miRNAs is implicated in several 88 
diseases, including OA [9–11].  miRNAs can promote cell differentiation by modulating 89 
expression of catabolic genes; for instance, miR-139 which is increased in OA cartilage 90 
inhibits cell proliferation by suppressing expression of insulin-like growth factor 1 receptor 91 
(IGF1R) and eukaryotic translation initiation factor 4 gamma 2 (EIF4G2) [12]. Furthermore, 92 
miRNA expression can also regulate proinflammatory cytokines, again contributing to 93 
altered expression of OA-inducing genes; for example, in lipopolysaccharide (LPS)-treated 94 
mouse chondrocytes, inhibition of miR-203 increases apoptosis and further stimulates the 95 
production of inflammatory cytokines [13]. Additionally, miRNAs can play cartilage-96 
protective roles; miR-193b-3p inhibits extracellular matrix (ECM) degradation through 97 
inhibition of inducible nitric oxide (NO) synthesis [14]; dysregulation of miR-193b-3p can 98 
therefore promote cartilage degeneration. Comprehensive reviews on miRNAs involved in 99 
osteoblastogenesis and osteoclastogenesis, chondrogenesis and cartilage degradation, 100 
synovial inflammation and neurogenesis can be found elsewhere [15–17].  101 
miRNAs can be found intracellularly or extracellularly, circulating in virtually any biological 102 
fluid in a remarkably stable manner [18–20]. Because biological fluids are generally 103 
obtainable through minimally invasive techniques, circulating miRNAs are attractive 104 
candidates for disease diagnosis, monitoring and prognostication [21, 22]. Interest in other 105 
classes of small non-coding RNAs such as small nucleolar RNAs (snoRNAs) has recently 106 
emerged. Mostly known for their housekeeping functions, snoRNAs have canonical roles in 107 
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the chemical modification of RNA substrates such as ribosomal RNAs, but can also exhibit 108 
miRNA-like activity [23]. Aberrant expression of snoRNAs has also been associated with the 109 
development of different diseases and a recent study found alterations in the snoRNA 110 
profile of OA joints in mice when compared to healthy controls, highlighting the potential of 111 
snoRNAs to be used as novel markers for this disease [24]. 112 
Equine miRNAs have been identified in numerous healthy tissues [25, 26] and their potential 113 
role in different diseases such as osteochondrosis, rhabdomyolysis and insulin resistance has 114 
also been investigated [27–29]. However, information on miRNA influence on the 115 
pathogenesis of equine OA is still lacking. Synovial fluid represents a reliable source of 116 
chemical information that can accurately reflect pathological conditions affecting the joint 117 
due to its functional proximity within joint tissues  [30]. In 2010, Murata et al. investigated 118 
the presence and stability of miRNAs in human synovial fluid for the first time, and found 119 
five differentially expressed miRNAs in OA patients compared to healthy controls, 120 
supporting the potential use of synovial fluid miRNAs as diagnostic biomarkers [11]. More 121 
recently, a screening of 752 miRNAs in synovial fluid from human patients with early- and 122 
late-stage OA demonstrated seven upregulated miRNAs in late-stage OA, irrespective of 123 
age, gender and body mass index [31]. Intra-articular treatment with hyaluronic acid was 124 
shown to modify miRNA expression in OA patients [32]. Although miRNA expression has not 125 
yet been investigated in equine OA, a preliminary study has recently described a 126 
reproducible method for miRNA isolation from equine synovial fluid and blood plasma [33]. 127 
With growing evidence of alterations in small non-coding RNA patterns in the synovial fluid 128 
of OA joints, we theorised that early stages of OA would affect these molecules and 129 
potentially provide early biomarkers for OA in equine patients. Examining expression of 130 
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small non-coding RNAs in synovial fluid in early OA may also provide further insights on the 131 
pathological changes that occur. Therefore, we investigated the profile of small non-coding 132 
RNAs of early equine OA synovial fluid using next generation sequencing. 133 
 134 
RESULTS 135 
Macroscopic and histological assessment 136 
The donors used for small RNA sequencing were selected from an elderly population of 137 
horses to account for any age-related changes. The ages of the control (mean±standard 138 
deviation; 22±2 years) and early OA (27±7.5 years) groups were not significantly different. 139 
Horses included in the control group presented minor macroscopic or histological changes , 140 
which are to be expected in healthy older animals. Horses included in the early OA group 141 
presented intermediate OA scores and were not obviously lame prior slaughter, suggestive 142 
of primary OA. 143 
 For samples used for small RNA sequencing there was a significant increase in the 144 
macroscopic score between control (1.0±0.5) and early OA (5.4±1.9, P=0.04). Likewise, there 145 
was a significant increase in the histological score between control (2.1±0.7) and early OA 146 
(6.1±1.5, P=0.01) (Additional File 1).  147 
For the independent cohort the ages of the control and early OA groups were not 148 
significantly different (Additional File 1). There was a significant increase in the macroscopic 149 
score between control (1.75±1.5) and early OA (3.6±0.9, P=0.04) samples. Similarly, there 150 
was a significantly increase in the histological score between control (1.5 ±1.3) and early OA 151 
(5.8±2.5, P=0.02) (Additional File 1). 152 
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Analysis of small RNA sequencing data 153 
Summaries of raw, trimmed reads and mapped reads to the Equus caballus database are in 154 
Additional File 2. There were 323 small non-coding RNAs identified. The categories of RNA 155 
identified are in Figure 1A and included small non-coding RNAs; miRNAs, snoRNAs and small 156 
nuclear RNAs (snRNAs).  157 
In total, the expression of 22 small noncoding RNAs; snoRNAs, snRNAs and miRNAs were 158 
significantly different in early OA synovial fluid (±1.3 log2 fold change (logFC), and P < 0.05) 159 
(Figure 1B; Table 1). We further generated a heatmap of the differentially expressed small 160 
non-coding RNAs (Figure 1C). 161 
 162 
Table 1. Differentially expressed small non-coding RNAs in early OA synovial fluid. 163 
Ensembl Gene Identification Gene Name Gene 
Biotype 
logFC early 
versus control 
P value early 
versus 
control 
ENSECAG00000025823 eca-let-7a-2 miRNA 1.39 0.02 
ENSECAG00000026330 eca-mir-10a miRNA -2.49 0.00 
ENSECAG00000026319 eca-mir-125a miRNA -1.43 0.05 
ENSECAG00000026274 eca-mir-143 miRNA -1.87 0.04 
ENSECAG00000026469 eca-mir-223 miRNA -2.00 0.01 
ENSECAG00000025270 eca-mir-23b miRNA 1.77 0.03 
ENSECAG00000025913 eca-mir-378 miRNA -1.34 0.04 
ENSECAG00000025243 eca-mir-99a-2 miRNA -1.29 0.02 
ENSECAG00000025456 ENSECAG00000025456 miRNA -1.74 0.02 
ENSECAG00000025697 ENSECAG00000025697 miRNA 1.31 0.03 
ENSECAG00000025869 ENSECAG00000025869 miRNA 1.44 0.02 
ENSECAG00000026713 ENSECAG00000026713 miRNA -7.27 0.03 
ENSECAG00000027105 ENSECAG00000027105 miRNA -1.34 0.04 
ENSECAG00000027634 ENSECAG00000027634 miRNA -1.77 0.04 
ENSECAG00000027641 SCARNA3 snoRNA -7.28 0.03 
ENSECAG00000026609 snoR38 snoRNA 8.01 0.01 
ENSECAG00000025929 SNORD96 snoRNA 7.61 0.01 
ENSECAG00000027243 snoU13 snoRNA 2.02 0.04 
ENSECAG00000025371 U11 snRNA 1.45 0.03 
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ENSECAG00000025759 U12 snRNA 2.70 0.00 
ENSECAG00000025571 U2 snRNA 2.57 0.00 
ENSECAG00000025679 U2 snRNA 2.49 0.00 
ENSECAG00000026075 U2 snRNA 2.52 0.00 
ENSECAG00000026524 U2 snRNA 2.43 0.00 
ENSECAG00000026243 U2 snRNA 2.51 0.00 
ENSECAG00000025523 U2 snRNA 1.48 0.03 
ENSECAG00000025597 U2 snRNA 1.57 0.04 
ENSECAG00000025663 U5 snRNA 3.11 0.00 
ENSECAG00000026081 U5 snRNA 1.92 0.01 
 164 
Confirmation of differential gene expression using qRT-PCR 165 
Seven small non-coding RNAs (miR-143, miR-223, miR-99a, miR-23b, let-7a-2, snord96A, 166 
snord13) were selected for further validation based on our current work, level of differential 167 
expression (P< 0.05 and logFC> 1.2) and following a literature review of differentially 168 
expressed genes. An independent cohort of synovial fluid samples was used, comprising of 169 
control (n=6, histological score 1.5 ±1.3) and early OA (n=6, histological score 5.8±2.5) 170 
synovial fluid samples. In agreement with the sequencing data miR-223 was significantly 171 
reduced in early OA and miR-23b, let-7a-2, snord96A and snord13 were significantly 172 
increased in early OA (Figure 2). For two miRNAs, miR-143 and miR-99a-2 quantitative 173 
reverse transcription-polymerase chain reaction (qRT-PCR) findings did not validate 174 
sequencing findings; despite being decreased in the OA group in our sequencing data, qRT-175 
PCR showed increased expression of both miRNAs in the independent OA group compared 176 
to controls, although this was not statistically significant (Figure 2). 177 
 178 
 179 
 180 
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Identification of potential target mRNA genes of the differentially expressed miRNAs 181 
With the goal of exploring potential biological associations with the differentially expressed 182 
miRNAs in early OA synovial fluid we undertook an Ingenuity Pathway Analysis (IPA) ‘Core 183 
Analysis’ on these. Interesting features were determined from the gene networks inferred. 184 
Significant cellular actions deduced by the differentially expressed miRNAs included 185 
apoptosis (P<0.0003), necrosis (P<0.0009), autophagy (P<0.0007) and inflammation 186 
(P<0.00001) (Figure 3A). 187 
Next, we undertook analysis to determine the mRNA targets of the differentially expressed 188 
miRNAs. Eight miRNAs were differentially expressed in early OA compared to non-OA 189 
controls. Once a conservative filter was applied (only miRNAs with experimentally 190 
confirmed or highly conserved predicted targets), miR-let7a-2 and miR-378 were excluded. 191 
Six miRNAs remained which collectively putatively target 993 mRNAs. We then additionally 192 
added the filters chondrocytes, fibroblast and osteoblasts, removed duplicates and obtained 193 
a list of 57 mRNA targets (Additional File 3). 194 
The presumed target mRNAs were input into the gene ontology (GO) tool PANTHER and the 195 
biological processes were summarised in REViGO and visualised using Cytoscape (Figure 3B). 196 
The top biological processes were regulation of cell population proliferation (false discovery 197 
rate (FDR)-adjusted P= 6.24E-13), cellular response to chemical stimulus (FDR = 4.54E-12) and 198 
cell surface receptor signalling pathway (FDR= 6.39E-12) (Additional File 4). 199 
 200 
 201 
 202 
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DISCUSSION 203 
The inability to detect pre-clinical changes in OA has been one of the main impediments to 204 
the development of effective therapies against this disease [34]. From a biomarker 205 
perspective, profiling synovial fluid circulating locally within the affected joint cavity at an 206 
early stage may provide new insights into pathological changes occurring during OA 207 
initiation and progression, and ultimately allow for the implementation of new therapeutic 208 
approaches. Our study is, to the best of our knowledge, the first to characterise the small 209 
non-coding RNA profile of synovial fluid in early OA in horses, providing evidence of a 210 
pattern of differential expressed synovial fluid miRNAs and other small non-coding RNAs in 211 
early OA synovial fluid when compared to our control samples.  212 
Osteoarthritis is a highly heterogeneous disease and can be broadly divided into primary, 213 
naturally occurring OA, which is chronic and associated with age; and post-traumatic OA, 214 
usually related to athletic use [35]. Whilst post-traumatic OA is highly prevalent and has a 215 
significant economic impact particularly for younger and athletic horses  [36], animals over 216 
15 years comprise up to one third of the equine population and represent a growing 217 
proportion of referral hospital admissions [37]. Musculoskeletal conditions are a major 218 
reason for euthanasia in older horses, suggesting that the social economic burden of age-219 
related osteoarthritis is rising [2]. While trauma might be one of the causative factors of OA 220 
in older horses, it is difficult to ascertain whether the body’s response to external sources of 221 
stress is being affected by ageing or whether age-related changes are actually a 222 
predisposing factor for traumatic injuries by increasing their likelihood, for example through 223 
altered biomechanics. For this reason, in our study we sought to exclude the cofounding 224 
effect of a traumatic injury by selecting older donors originating from the abattoir; although 225 
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this does not guarantee absence of a traumatic injury, horses can only enter the food chain 226 
if they are not obviously lame prior to slaughter, making it more likely that these OA cases 227 
arise from age-related molecular mechanisms. Selected donors from both control and early 228 
OA groups were age-matched to account for any age-related changes. Donors from the 229 
control group presented minor changes in their joints which are to be expected in older 230 
horses, hence classifying this group as “control” as opposed to “healthy”.  231 
Due to the considerable interest in miRNA-mediated gene regulation in recent years, the list 232 
of miRNAs possibly implicated in OA and other joint related pathologies has grown [16]. 233 
miRNAs that are differentially expressed in joint tissues of patients with OA are likely to 234 
contribute to OA pathophysiology and may be utilised as diagnostic factors [38]. One 235 
example is miR-140, which is significantly downregulated in human OA cartilage [10] and is 236 
thought to attenuate OA progression by modulating ECM homeostasis [39]; also, 237 
dysregulation of miR-140-3p and-5p in synovial fluid has been correlated with OA severity 238 
[40]. 239 
Among the differentially expressed miRNAs found in our study, miR-23b was significantly 240 
increased in the early OA cohort. miR-23b is thought to be involved in OA progression by 241 
targeting cartilage-associated protein (CRTAP) and thus influencing cartilage homeostasis 242 
[41]. This miRNA has also been shown to positively regulate the chondrogenic 243 
differentiation of mesenchymal stem cells by regulating the expression of sex-determining 244 
region Y-Box 9 (SOX9) and protein kinase A (PKA) [42, 43]. 245 
Likewise, we found let-7a-2 to be upregulated in early OA. In an experiment comparing 246 
miRNA expression in synovial fluid from human OA patients undergoing hyaluronic acid 247 
treatment, let-7a was significantly upregulated in synovial fluid of OA samples compared to 248 
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healthy controls; levels of let-7a in affected patients returned to normal after hyaluronan 249 
injection [32]. Let-7a is thought to regulate IL-6 receptor (IL6R), and its inhibition can 250 
enhance cell proliferation, reduce apoptosis and inhibit inflammatory response in ATDC5 251 
cells in a LPS-induced in vitro model of OA [44]. Members of the let-7 family have often been 252 
described in studies involving OA; a large population-based study identified serum let-7e as 253 
a promising candidate to predict OA risk, independent of age, sex and body mass index [45]. 254 
A recent investigation supported this claim, providing further evidence of decreased 255 
expression of let-7e in serum of patients affected with knee OA [46]. The exact roles of 256 
miRNAs of the let-7 family remain unclear, but the evidence for their use as biomarkers for 257 
OA is growing. 258 
In the above mentioned paper by Xu et al. (2015) [32], miR-223 was also significantly 259 
upregulated in synovial fluid of OA patients prior to intra-articular injection of hyaluronan. 260 
miR-223 participates in cartilage homeostasis and structure by targeting growth 261 
differentiation factor 5 (GDF5) [41]. Early-stage OA patients showed upregulation of miR-262 
223 in peripheral blood mononuclear cells, with its expression decreasing as OA progressed 263 
[47]. In our study, we found miR-223 to be downregulated in the synovial fluid of the early 264 
OA cohort, which supports the involvement of this miRNA in the early osteoarthritic 265 
process. miRNA regulation is complex and differences between our results and previously 266 
published literature in human patients may be due to different stages in osteoarthritic 267 
process; species variation may also partially justify these disparities. Additionally, an 268 
increasing body of evidence demonstrates that long non-coding RNAs (lncRNAs) can act as 269 
sponges for microRNAs [48]; a previous study found that the expression of miR-223 was 270 
restrained by lncRNA activated by transforming growth factor beta (lncRNA-ATB) [49] which 271 
might contribute to variations in miRNA expression.  272 
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We have previously shown the involvement of snoRNAs in cartilage ageing and OA and their 273 
potential use as biomarkers for OA [24]. In this study we identified for the first time snord13 274 
and snord96a as highly expressed small non-coding RNAs in early OA. Our previous work in 275 
human OA cartilage identified a dysregulation in SNORD96A expression in ageing and OA. In 276 
addition, we demonstrated changes in chondrogenic, hypertrophic, ribosomal RNA (rRNA) 277 
and OA related gene expression following overexpression and knockdown of SNORD96A in 278 
human chondrocytes. Interestingly we also identified an increase in SNORD96A in 279 
chondrocytes treated with OA synovial fluid [50]. In another microarray study of young 280 
compared to old OA cartilage we identified SNORD13 was increased in OA cartilage [51]. 281 
Together these findings indicate that changes in synovial fluid snoRNAs could in part be due 282 
to a dysregulation in their expression in cartilage in OA. snoRNAs are emerging with 283 
unappreciated functional roles in cell physiology [52] and our results support our earlier 284 
work for the potential use of snoRNAs as novel biomarkers in OA [24].  285 
Predicted targets of the miRNAs of interest appear to be involved in processes of 286 
inflammation and cellular destruction including necrosis, apoptosis and autophagy, which 287 
have been previously shown to contribute to the pathogenesis of OA in human patients 288 
through pro-inflammatory cytokines production [53], synovial inflammation [54] and 289 
chondrocyte apoptosis [55]; subchondral bone changes [56] and chondrocyte apoptosis [57] 290 
have also been implicated in the pathogenesis of OA in horses. 291 
For example, a disintegrin and metalloproteinase with thrombospondin motif 1 (ADAMTS1) 292 
is known to cleave aggrecan, a critical component for cartilage structure [58]; bone 293 
morphogenetic protein (BMP) receptor type 1B (BMPRB) is a receptor for BMP, and BMP 294 
signalling is essential for chondrocyte proliferation, survival and differentiation [59]; and IL-295 
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6R interacts with IL-6, one of the pro-inflammatory cytokines increased in osteoarthritis 296 
[60]. Experimental validation of these and other predicted target genes can clarify biological 297 
mechanisms behind small non-coding RNAs of interest and elucidate their role in the 298 
pathogenesis of OA; this is critical for the success of future interventions, as these molecules 299 
can be targeted in a specific manner [61, 62].  300 
Profiling circulating, cell-free small non-coding RNAs is generally a challenging task due to 301 
the limited amount of RNA present in biofluids, as well as presence of inhibitory compounds 302 
which potentially hinder downstream enzymatic processes. However, liquid biopsies  for the 303 
investigation of non-coding RNA profiles have gained prominence due to their ease of 304 
collection and potential use as diagnostic tools. Future studies in this field would benefit 305 
from analysing larger cohorts of patients; our study was limited by the availability of joints 306 
with early OA, resulting in a small sample size. Notwithstanding, a previous study on the 307 
subject of RNA-Seq analysis performance [63] has shown the number of genes called 308 
significant increases as the sample number increases; this suggests that for pipelines such as 309 
the one used in this study, having a slightly underpowered approach means we are more 310 
likely to underestimate rather than overestimate the number of differentially expressed 311 
miRNAs. That fact that we were able to validate our findings  through qRT-PCR in an 312 
independent cohort solidifies our findings, despite the small sample size. Further work is 313 
unquestionably needed, yet this experiment enabled us to identify small non-coding RNA 314 
changes in the initial and an additional cohort and revealed, for the first time, the potential 315 
use of small non-coding RNAs as biomarkers for early OA. These results support the use of 316 
synovial fluid small non-coding RNAs as molecular biomarkers for early disease in OA joints. 317 
Our future research is currently ascertaining the applicability of these findings in a clinical 318 
setting.  319 
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CONCLUSIONS 320 
This study demonstrates that equine synovial fluid displays a pattern of small non-coding 321 
RNA differential expression in early OA when compared to controls, as defined by gross and 322 
histological scoring and many of these small non-coding RNAs have previously been 323 
demonstrated to have a role in OA. The affected biological cellular processes in response to 324 
changing miRNAs and their target genes might play an important role in early OA 325 
pathogenesis. This opens the possibility of a relatively non-invasive method for early 326 
detection of OA. Furthermore, characterisation of these dynamic molecular changes could 327 
provide novel insights on the process and mechanism of early OA development. 328 
 329 
METHODS 330 
All reagents were from ThermoFisher Scientific, unless stated. 331 
 332 
Sample collection and preparation 333 
Samples were collected from the metacarpophalangeal joints of horses from an abattoir as 334 
a by-product of the agricultural industry. Specifically, the Animal (Scientific procedures) Act 335 
1986, Schedule 2, does not define collection from these sources as scientific procedures. 336 
Ethical approval was therefore not required.  337 
The joints were aseptically dissected to allow visual inspection of the metacarpus, the 338 
proximal phalange and the sesamoids. All joints were photographed and macroscopic 339 
changes were scored based on a scoring system as previously described [64]. Synovial fluid 340 
was aseptically collected directly from the open joint with a 5 ml sterile syringe, immediately 341 
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placed on sterile microcentrifuge tubes on ice and centrifuged for 10 min at 3000 g and 4°C 342 
to remove cells and debris. The supernatant was collected and stored at -80°C. A cartilage 343 
and subchondral bone fragment was collected from the palmar aspect of one of the 344 
metacarpal condyles, fixed on paraformaldehyde and sent for histology; histological scoring 345 
was performed using the previously described scoring system [65].   346 
Donors were assigned to groups based on the macroscopic and histologic scoring. The 347 
control (non-OA) group was comprised of 3 donors with age mean± standard deviation 22±2 348 
years; while the early OA group was comprised of 3 donors with 22±7.5 years.  349 
 350 
 351 
RNA isolation, cDNA library preparation and small RNA sequencing 352 
Synovial fluid was treated to reduce viscosity with 1µg/ml of hyaluronidase at 37˚C for 1 hr, 353 
centrifuged at 1000 g for 5 min, and supernatant used for total RNA extraction using 354 
miRNeasy serum kits (Qiagen, Crawley, UK). The integrity of the RNA was assessed on the 355 
Agilent 2100 Bioanalyzer system using an RNA Pico chip. 100ng samples were submitted for 356 
library preparation using NEBNext® Small RNA Library Prep Set for Illumina (New England 357 
Biosciences (NEB), Ipswich, USA) but with the addition of a Cap-Clip™ Acid Pyrophosphatase 358 
(Cell script, Madison, USA) step to remove any 5’ cap structures [24] and size selected using 359 
a range 120-300bp. This enabled both miRNAs and snoRNAs to be identified in a non-biased 360 
approach. The pooled libraries were sequenced on an Illumina HiSeq4000 platform with 361 
version 1 chemistry to generate 2 x 150 bp paired-end reads. Data has been submitted to 362 
National Centre for Biotechnology Information; accession E-MTAB-8409. 363 
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Small RNA sequencing data analysis 364 
Sequence data were processed through a number of steps to obtain non-coding RNA 365 
expression values including; basecalling and de-multiplexing of indexed reads using CASAVA 366 
version 1.8.2; adapter and quality trimming using Cutadapt version 1.2.1 [66] and Sickle 367 
version 1.200 to obtain fastq files of trimmed reads; aligning reads to horse genome 368 
reference sequences (release 90) from Ensembl using Tophat version 2.0.10 [67] with option 369 
“–g 1”; counting aligned reads using HTSeq-count [68] against the features defined in horse 370 
genome GTF file (release 90).  371 
Differential expression analysis was performed in R using package DESeq2 [69]. The 372 
processes and technical details of the analysis include; assessing data variation and 373 
detecting outlier samples through comparing variations of within and between sample 374 
groups using principle component analysis (PCA) and correlation analysis; handling library 375 
size variation using DESeq2 default method; formulating data variation using negative 376 
binomial distributions; modelling data using a generalised linear model; computing logFC 377 
values for control versus early OA based on model fitting results through contrast fitting 378 
approach, evaluating the significance of estimated logFC values by Wald test; adjusting the 379 
effects of multiple tests using FDR approach [70] to obtain FDR adjusted P-values. 380 
The Ensembl horse genome GTF file release 90 does not have mature miRNA features. We 381 
linked the defined miRNA primary transcripts to miRBase horse miRNA GFF3 file by feature’s 382 
genome coordinates so as to obtain the corresponding mature miRNA.  383 
 384 
 385 
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qRT-PCR validation 386 
Validation of the selected small RNA sequencing results in an independent cohort of equine 387 
metacarpophalangeal synovial fluid was undertaken using qRT-PCR. Six control (non-OA), 388 
mean±standard deviation (20.2±2.4 years) and six early OA (20.8±4.1) with macroscopically 389 
and histologically graded sample scores similar to those used for sequencing were used. 390 
Total RNA was extracted as above. Small non-coding RNAs were chosen based on our 391 
current work, level of differential expression (P< 0.05 and logFC> 1.2) and following a 392 
literature review of differentially expressed genes. These were miR-143, miR-223, miR-99a, 393 
miR-23b, let-7a-2, snord96A and snord13. Primer sequences/assays used can be found in 394 
Additional File 5. PolyA cDNA was synthesized using 200ng RNA and the miScript II RT Kit. A 395 
mastermix was prepared using the miScript SYBR Green PCR Kit (Qiagen, Crawley, UK) and 396 
the appropriate bespoke designed miScript Primer Assays (Qiagen, Crawley, UK). Real-time 397 
PCR was undertaken using a LightCycler® 96 system (Roche). Steady-state transcript 398 
abundance of potential endogenous control genes was measured in the small RNA 399 
sequencing data. Assays for four genes – miR-181a, miR-100, miR-191a and U6 were 400 
selected as potential reference genes because their expression was unaltered in this study. 401 
Stability of this panel of genes was assessed by applying a gene stability tool RefFinder [71]. 402 
The geometric mean of miR-100 and miR-191a was selected as the stable endogenous 403 
control. miR-100 has been previously used as a normaliser in a similar study as it was 404 
identified by NormFinder as the most stable [31]. Relative expression levels were 405 
normalised to the geometric mean of miR-100 and miR-191 and calculated using the 2^-DCT 406 
method [72].  407 
 408 
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miRNA target prediction and pathway analysis 409 
Potential biological associations of the differentially expressed miRNAs in early OA synovial 410 
fluid were identified using IPA (IPA, Qiagen Redwood City, CA, USA) ‘Core Analysis’. 411 
Canonical pathways, novel networks, and common upstream regulators were then queried. 412 
Additionally in order to identify putative miRNA targets, bioinformatic analysis was 413 
performed by uploading differentially expressed miRNA data into the MicroRNA Target 414 
Filter module within IPA software. This identifies experimentally validated miRNA-mRNA 415 
interactions from TarBase, miRecords, and the peer-reviewed biomedical literature, as well 416 
as predicted miRNA-mRNA interactions from TargetScan. We used a conservative filter at 417 
this point, using only experimentally validated and highly conserved predicted mRNA targets 418 
for each miRNA. Targets were then also filtered on the cells chondrocyte, osteoblasts and 419 
fibroblasts (the latter two settings were the nearest to bone and synovial cells  available for 420 
selection), to represent joint cells in contact with synovial fluid.   421 
PANTHER (GO Ontology database 2020-02-21) [73] was used for overrepresentation analysis 422 
of the mRNA targets using Fisher’s Exact test with FDR correction. This tests whether the 423 
input mRNAs associate significantly with specific pathways and generates a list of biological 424 
process GO terms. Terms with FDR adjusted P < 0.05 were summarised using REViGO [74] 425 
with allowed similarity of 0.4 and visualised using Cytoscape [75]. 426 
 427 
Statistical analysis 428 
The heatmap and volcano plots were made using MetaboAnalyst 3.5 429 
(http://www.metaboanalyst.ca) which uses the R package of statistical computing software 430 
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[76]. For statistical evaluation of gene expression data, following normality testing , Mann-431 
Whitney tests were performed using GraphPad Prism version 8.0 for Windows (GraphPad 432 
Software, La Jolla California USA, www.graphpad.com); P values are indicated. 433 
 434 
LIST OF ABBREVIATIONS 435 
ADAMTS1 = a disintegrin and metalloproteinase with thrombospondin motif 1, BMP = bone 436 
morphogenic protein, BMPRB = BMP receptor type 1B, CRTAP = cartilage associated protein, 437 
DNA = deoxyribonucleic acid, ECM = extracellular matrix, EIF4G2 = eukaryotic translation 438 
initiation factor 4 gamma 2, FDR = false discovery rate, GDF5 = growth differentiation factor 439 
5, GO = gene ontology, IGF1R = insulin-like growth factor 1 receptor;  IPA = Ingenuity 440 
Pathway Analysis, IL = interleukin, IL6R = interleukin 6 receptor, LPS = lipopolysaccharide, 441 
logFC = log2 fold change, lncRNA = long non-coding RNA, lncRNA-ATB = lncRNA activated by 442 
transforming growth factor beta, miRNAs = micro RNAs, NO = nitric oxide, OA = 443 
osteoarthritis, PCA = principal component analysis, PKA = protein kinase A, qRT-PCR = 444 
quantitative reverse transcription polymerase chain reaction, RNA = ribonucleic acid, Rrna = 445 
ribosomal RNA, sncRNAs = small non-coding RNAs, snoRNAs = small nucleolar RNAs, snRNAs 446 
= small nuclear RNAs, SOX9 = sex-determining region Y – box 9. 447 
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 691 
FIGURE LEGENDS 692 
Figure 1. Overview of HiSeq data from equine synovial fluid in control and early OA. (A) 693 
Categories of RNAs identified in normal and early OA synovial fluid. (B) Volcano plot of small 694 
non-coding RNAs identified represents logFC and –log10 P value. Pink dots represent 695 
differentially expressed small non-coding RNAs. (C) A heatmap representation of the 696 
differentially expressed small non-coding RNA reads from control (non-OA) and early OA 697 
equine synovial fluid. Two-dimensional grid matrix displaying columns referring to the 698 
control (non-OA) and early OA samples and rows of small non-coding RNAs identified by 699 
their Ensembl identification. The heatmap was generated using log-transformed normalised 700 
read counts, normalisation was performed by EdgeR's trimmed mean of M values. The 701 
colour of each entry is determined by the number of reads, ranging from red (negative 702 
values) to yellow (positive values). 703 
 704 
Figure 2. Validation of small non-coding RNAs differentially expressed following small RNA 705 
sequencing in an independent cohort using qRT-PCR. RNA extracted from the synovial fluid 706 
of six healthy control donors and six early OA donors. Histograms of the relative expression 707 
calculated using 2^-DCT method using the geometric mean of miR-100 and miR191 as an 708 
endogenous control. All qRT-PCR reactions were performed in triplicate. Statistical 709 
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significance was tested in Graphpad Prism using a Mann Whitney test. Bars represent means 710 
with standard error of the mean. P<0.05; * 711 
 712 
Figure 3. (A) Ingenuity Pathway Analysis (IPA) derived actions of differentially expressed 713 
miRNAs in early OA synovial fluid. IPA identified that cellular actions apoptosis, necrosis, 714 
autophagy and inflammation were associated with the differentially expressed miRNAs. 715 
Figures are graphical representations of molecules identified in our data in their respective 716 
networks. Red nodes; upregulated in early OA, and green nodes; downregulated gene 717 
expression in early OA synovial fluid. Intensity of colour is related to higher fold-change. 718 
Legends to the main features in the networks are shown. The actions colour is dependent 719 
on whether it is predicted to be activated or inhibited. (B) The position of differentially 720 
expressed miRNAs in the chondrocyte/fibroblast/osteoblast expression network. PANTHER 721 
was used to identify gene ontology (GO) biological processes associated with predicted 722 
mRNA targets and perform overrepresentation analysis to highlight the GO terms most 723 
significantly affected by dysregulated miRNA-mRNA interactions in early OA synovial fluid. 724 
GO terms (FDR< 0.05) were summarised and visualised using REViGO and Cytoscape. 725 
Allowed similarity setting in REViGO was tiny (0.4). The line width specified the amount of 726 
similarity. 727 
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Additional file 1. Histograms of age, gross score and Modified Mankin’s Score for 739 
dependent and independent equine donor cohorts (.tiff). Expressions are means and error 740 
bars ± standard error means. Statistical analysis undertaken in GraphPad Prism 8.0 using a 741 
Mann Whitney Test. P values *; P <0.05. 742 
 743 
Additional file 2. Summary of raw, trimmed reads and mapped reads (.xlsx). Summary of 744 
raw, trimmed reads and mapped reads to Equus caballus database, from analysis of small 745 
RNA sequencing data. 746 
 747 
Additional file 3. mRNA targets predicted by IPA (.xlsx). List of mRNA targets predicted by 748 
bioinformatic analysis with IPA software, using a conservative filter of only experimentally 749 
validated and highly conserved predicted mRNA targets for each miRNA. Targets were then 750 
also filtered on the cells chondrocyte, osteoblasts and fibroblasts  751 
 752 
Additional file 4. PANTHER GO terms FDR-adjusted P < 0.05 (.xlsx). List of GO terms with 753 
FDR-adjusted P < 0.05, obtained with PANTHER overrepresentation analysis of the mRNA 754 
targets using Fisher’s Exact test. 755 
 756 
Additional file 5. Primer sequences/assays used for detection of small non-coding RNAs 757 
through qRT-PCR analysis (.xlsx). For miRNAs and snoRNAs with sequences homologous to 758 
human, Qiagen primer assays were used. Remaining miRNA primers were customised using 759 
Eurogentec primer design. 760 
